Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?

doi:10.5152/tjg.2020.19569

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology - 1 Feb 2021

Demirtürk Neşe, Aygen Bilgehan, Çelik İlhami, Mıstık Reşit, Akhan Sıla, Barut Şener, Ural Onur, Batırel Ayşe, Şimşek Funda, Ersöz Gülden, İnan Dilara, Kınıklı Sami, Türker Nesrin, Bilgin Hüseyin, Gürbüz Yunus, Tülek Necla, Tarakçı Hüseyin, Yıldız Orhan, Türkoğlu Emine, Kamalak Güzel Deniz, Şimşek Sümeyra, Tuna Nazan, Aktuğ Demir Nazlım, Çağatay Atahan, Çetinkaya Rıza Aytaç, Karakeçili Faruk, Hakyemez İsmail Necati, Tuncer Ertem Günay, Örmen Bahar, Korkmaz Pınar, Yıldız Uluhan, Kuruüzüm Ziya, Şener Alper, Arslan Özel Selcan, Öztürk Sinan, Suer Kaya, Çelen Mustafa Kemal, Konya Petek, Asan Ali, Saltoğlu Neşe, Doğan Nurhan

Abstract excerpt

BACKGROUND: In this study, we aimed to investigate the efficacy and safety of sofosbuvir-based therapies in the treatment of chronic hepatitis C in real-world clinical practice. METHODS: Data from patients with chronic hepatitis C treated with SOF/LDV ± RBV or SOF/RBV in 31 centers across Turkey between April 1, 2017, and August 31, 2018, were recorded in a nationwide database among infectious disease...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzimidazoles

Share to Drug Therapy, Combination

Share to Fluorenes

Share to Hepatitis C

Share to Hepatitis C, Chronic

Share to Ribavirin

Share to Sofosbuvir

Share to Turkey

Source

Open in PubMed Open full text

Identifiers

PMID: 33960939
DOI: 10.5152/tjg.2020.19569
PMCID: PMC8975436

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?PMID 33960939Read ↗

Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience.Semantic proximity Read ↗

Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose.Semantic proximity Read ↗

Effectiveness and Safety of Sofosbuvir/Ledipasvir Treatment for Monoinfected Genotype 1 HCV Patients in Real-Life Clinical Practice: Results from Spanish Hepa-C CohortSemantic proximity Read ↗

Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study.Semantic proximity Read ↗

Hepatitis C: efficacy and safety in real life.Semantic proximity Read ↗

Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice.Semantic proximity Read ↗

Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study.Semantic proximity Read ↗

Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.Semantic proximity Read ↗

Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study.Semantic proximity Read ↗

Efficacy and Safety of Ledispavir/Sofosbuvir with or without Ribavirin in patients with Decompensated Liver Cirrhosis and Hepatitis C Infection: a Cohort Study.Semantic proximity Read ↗

Real-world safety and effectiveness of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C virus genotype 1 in Japan.Semantic proximity Read ↗

[Twelve-week of sofosbuvir/velpatasvir therapeutic regimen for chronic hepatitis C patients in northwest region of China: a real-world multicenter clinical study].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.